Capital International Investors Sells 1,526,537 Shares of Catalent, Inc. (NYSE:CTLT)

Capital International Investors decreased its position in shares of Catalent, Inc. (NYSE:CTLT) by 51.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,467,930 shares of the company’s stock after selling 1,526,537 shares during the quarter. Capital International Investors owned approximately 0.81% of Catalent worth $82,865,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in CTLT. Lindbrook Capital LLC grew its holdings in Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after acquiring an additional 208 shares in the last quarter. GAMMA Investing LLC bought a new position in Catalent in the fourth quarter worth approximately $33,000. Rakuten Securities Inc. purchased a new stake in Catalent during the fourth quarter worth $46,000. Federated Hermes Inc. bought a new stake in Catalent during the 4th quarter valued at $46,000. Finally, Mather Group LLC. purchased a new position in shares of Catalent in the 1st quarter valued at $52,000.

Catalent Price Performance

Shares of NYSE CTLT traded up $0.23 during trading on Friday, hitting $58.68. The company had a trading volume of 3,004,922 shares, compared to its average volume of 1,818,650. Catalent, Inc. has a fifty-two week low of $31.80 and a fifty-two week high of $60.20. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. The stock has a fifty day simple moving average of $56.21 and a two-hundred day simple moving average of $55.69. The firm has a market capitalization of $10.62 billion, a price-to-earnings ratio of -9.62, a price-to-earnings-growth ratio of 2.41 and a beta of 1.16.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). The business had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. On average, research analysts expect that Catalent, Inc. will post -0.17 earnings per share for the current year.

Insider Activity at Catalent

In other news, insider Ricky Hopson sold 1,401 shares of Catalent stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total transaction of $76,018.26. Following the sale, the insider now owns 20,617 shares of the company’s stock, valued at approximately $1,118,678.42. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, insider Ricky Hopson sold 1,401 shares of the stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the transaction, the insider now directly owns 20,617 shares in the company, valued at approximately $1,118,678.42. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Matti Masanovich sold 2,993 shares of the business’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $56.74, for a total transaction of $169,822.82. Following the completion of the sale, the chief financial officer now owns 33,871 shares in the company, valued at $1,921,840.54. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on CTLT. StockNews.com started coverage on Catalent in a research note on Wednesday. They issued a “sell” rating on the stock. Stephens reissued an “equal weight” rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 target price on shares of Catalent in a research note on Thursday, July 11th. Finally, Barclays boosted their target price on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, June 28th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Catalent has an average rating of “Hold” and an average price target of $55.65.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.